Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXVP13)

Drug Name
GI-129471 Drug Info
Synonyms
GI-129471; GI 129471; CHEMBL114427; 130370-59-1; AC1NX8L8; SCHEMBL6838720; DTXSID60156496; gi129471; BDBM50069608; GW9471; GW-9471; (2R-(1(S*),2R*,3S*))-N4-Hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((phenylthio)methyl)butanediamide; Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((phenylthio)methyl)-, (2R-(1(S*),2R*,3S*))-
Indication
Disease Entry ICD 11 Status REF
Inflammation 1A00-CA43.1 Terminated [1]
Cross-matching ID
PubChem CID
5748217
CAS Number
CAS 130370-59-1
TTD Drug ID
DMXVP13

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Preclinical Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Matrix metalloproteinase (MMP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Abametapir DM2RX0I Head and body lice 1G00.0 Approved [3]
BLZ-100 DMFKA4G Glioma 2A00.0 Phase 1/2 [4]
S-3304 DMCBQTF Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
ABT-518 DMA2RM3 Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [6]
D-1927 DM5D8JW Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [7]
S-3536 DMZYRI3 Osteoarthritis FA00-FA05 Discontinued in Phase 1 [8]
BB-2983 DMYK8OG Inflammatory bowel disease DD72 Discontinued in Phase 1 [9]
ONO-4817 DMKRVUN Inflammatory bowel disease DD72 Discontinued in Phase 1 [10]
DFD-11 DMHXVN1 Head and body lice 1G00.0 Application submitted [11]
D-9120 DMHNZ1P Inflammatory bowel disease DD72 Terminated [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Matrix metalloproteinase (MMP) TT1GHVO NOUNIPROTAC Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006709)
2 Stimulation of matrix metalloproteinase-9 expression in human fibrosarcoma cells by synthetic matrix metalloproteinase inhibitors. Exp Cell Res. 2002 Apr 15;275(1):110-21.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
5 Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther. 2005 Jun;43(6):282-93.
6 Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J Mass Spectrom. 2004 Mar;39(3):277-88.
7 Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. 1999 Mar15;59(6):1231-5.
8 CIINE Reflects Collagenase-Specific CII Breakdown in Cartilage Explant and Whole Body of Canine. Biomark Insights. 2013; 8: 77-83.
9 Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. J Vasc Surg. 2004 Feb;39(2):432-9.
10 ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res. 2000 Apr;49(4):144-6.
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12 WO patent application no. 2006,1139,93, Matrix metalloproteinase inhibitors of tgfss -induced subcapsular cataract formation.